NextCell has formally kicked-off its Eurostars funded project ‘ Bioscale ’

NextCell Pharma AB (publ) (“NextCell” or “the Company”) announces that Nasdaq Stockholm AB today has approved their application for trading on Nasdaq Stockholm First North. The last day for trading on Spotlight is Tuesday, July 21, 2020 and the first day for trading on Nasdaq First North is Wednesday, July 22, 2020. The shares in NextCell will be traded with unchanged ticker (NXTCL) and ISIN code (SE0009723125) and shareholders in NextCell need not take any action in connection with the list change. "The list change is a natural step in our development and is expected to attract a broader

The Board of Directors of NextCell Pharma AB ("NextCell" or the “Company”) announces today the outcome in the Company’s new issue of shares with preferential rights for existing shareholders (the “Rights Issue”). The demand was high and the Rights Issue was oversubscribed. Thus, no guarantees have been utilized. Through the Rights Issue, the Company receives approximately SEK 25.1 million before transaction costs. · 4,111,192 shares were subscribed using subscription rights · In addition, applications for subscription without using subscription rights corresponding to 11,750,102 shares

NextCell Pharma AB ("NextCell") announces that the last patient now has left ProTrans-2, meaning the phase II trial with the drug candidate ProTrans for treatment of type 1 diabetes, is completed according to plan. Data will be compiled and analyzed by independent statistician to be presented during the third quarter. “NextCell is now preparing a phase III trial in order to reach the market as soon as possible, in case of a positive result of the phase II study”, says Mathias Svahn, CEO. NextCell's drug candidate, ProTrans ™, developed for the treatment of type 1 diabetes, has, in

The Board of Directors of NextCell Pharma AB ("NextCell" or the “Company”) has prepared a prospectus (the “Prospectus”) relating to the new issue of shares with preferential rights for existing shareholders of approximately SEK 25.1 million (the Rights Issue”), which was resolved by the Board of Directors on 15 May 2020 and approved by the extraordinary general meeting on 3 June 2020. The Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority. Today, the Company also announces the intention of change of listing. The Company has obtained conditional

NextCell Pharma AB ("NextCell") has been invited to participate in the panel discussion entitled “The impact of corona virus on the global healthcare - new challenges and main problems”. Doctor Lindsay Davies, Chief Scientific Officer at NextCell and researcher at Karolinska Institutet will join the panel. Today, 28[th] of May, international experts are having a one-day video conference. The conference is hosted by the Polish Medical Research Agency, Ministry of Health, Ministry of Development and is organized by the Kulski Foundation. The panel discussion is at 15:15 with opening speech

NextCell Pharma AB ("NextCell" or the “Company”) announces that the Board of NextCell Pharma AB has resolved to conduct a fully guaranteed new issue of shares of approximately SEK 25.1 million with preferential rights for the Company's existing shareholders (the "Rights Issue"), subject to approval by an extraordinary general meeting in the Company. The Company’s largest shareholder Diamyd Medical AB and chairman of the Boad of Directors Anders Essen-Möller have undertaken to subscribe for their pro rata share in the Rights Issue. In total, the Rights Issue is covered by subscription

NextCell Pharma AB (publ) (NXTCL) today announces that its Interim report for the period September 1, 2019 - February 29, 2020 now is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-reports Second quarter (2019-12-01 until 2020-02-29) · Operating income amounted to SEK 1 364 645 (435 051). · Operating result amounted to SEK -4 228 449 (-3 552 444). · Earnings per share* amounted to SEK -0,22 (-0,31). · Cash and bank amounted to SEK 10 700 725 (6 886 879). · Solidity** amounted to 80,2 (85,0) %. First six month (2019-09-01

NextCell Pharma AB ("NextCell") announces that parallel discussions with several hospitals have been initiated to treat patients with covid-19, the severe respiratory tract infection caused by the new coronavirus, with the stem cell product ProTrans. “We would like to emphasize that this information is preliminary. There are both administrative and regulatory challenges, but the intention from healthcare is to go forward with this. We will come back when and if further information is available, says Mathias Svahn, CEO of NextCell. "We advise against speculative share purchases in the